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Angiogenic Growth Factors and Their Receptors in
First-Trimester Human Decidua of Pregnancies Further
Complicated By Preeclampsia or Fetal Growth Restriction
M. Plaisier, MD, E. Streefland, MD, P. Koolwijk, PhD,
V.W. M. van Hinsbergh, PhD, F. M. Helmerhorst, MD, and J. J. H. M. Erwich MD, PhD
Disturbances in decidual and placental vascular development may play a role in the pathogenesis of preg-
nancy complications. This study focused on the role of angiogenic factors in the first trimester in the
pathogenesis of preeclampsia (PE) and/or fetal growth restriction (FGR). First-trimester decidua was
obtained during chorionic villous sampling.The expression of the angiogenic factors was determined by
reverse transcriptase polymerase chain reaction and related to the pregnancy outcome. First-trimester
decidua expressed all angiogenic factors.The differential expression of angiogenic factors appeared to be
more prominent in FGR than in PE.These first-trimester samples provided a unique opportunity to
obtain information regarding the onset of PE and FGR. First-trimester changes in angiogenic factor
expression may well occur as a compensatory mechanism.This, in turn, may unintentionally set the stage
for increased angiogenesis and altered decidual/placental vascular adaptation, which may be part of the
pathogenesis of PE and/or FGR.
KEY WORDS: Angiogenic factors, first trimester, decidua, preeclampsia,
fetal growth restriction.
(proteinuria), and the uteroplacental unit (fetal distress
and growth restriction). Failure of placental vascular devel-
opment has been linked to the pathogenesis of PE and
FGR.4,5
Decidual vascular adaptation to pregnancy is charac-
terized by high levels of both angiogenesis, the formation
of new vessels from existing vasculature, and vasculogen-
esis, blood vessel generation from angioblast precursor
cells.6,7 Additionally, vascular mimicry or pseudovasculo-
genesis is also taking place where cytotrophoblasts con-
vert to an endothelial phenotype. Failure of angiogenesis
and pseudovasculogenesis has been proposed as processes
in the inception of PE and FGR.8
Numerous factors are thought to play a role in nor-
mal vascular adaptation to implantation.9 Vascular
endothelial growth factor-A (VEGF-A) and placental
growth factor (PlGF) are probably the best-studied fac-
tors.10-12 VEGF interacts with VEGFR-1 (Flt-1) and
VEGFR-2 (KDR) to promote endothelial cell prolifera-
tion, cell migration, and vascular permeability. In rabbits,
VEGF, together with its receptor Flt-1, plays an active
role in the angiogenic process during implantation.10
Disturbances in decidual and placental vasculardevelopment may play a role in complications ofpregnancy, like preeclampsia (PE) and fetal
growth restriction (FGR).1-3 Preeclampsia affects 5% to
10% of pregnancies and is responsible for substantial mater-
nal and neonatal morbidity and mortality. Predominant
features are maternal systemic vascular endothelial dys-
function and microangiopathy.Target organs are the brain
(seizures or eclampsia), liver (hemolysis, elevated liver
enzymes, low platelets [HELLP] syndrome), kidney
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PlGF shares biochemical and functional features with
VEGF and interacts with VEGFR-1 (Flt-1). PlGF and
VEGF-A have synergistic effects regarding angiogenesis,
but vessels induced by PlGF are more mature and stable
than vessels induced byVEGF-A.13,14 PlGF is abundantly
expressed in the human placenta. Both VEGF-A and
PlGF may be important paracrine regulators of decidual
angiogenesis and autocrine mediators of trophoblast
function.11,15 The soluble variant of Flt-1 has been associ-
ated with the pathogenesis of PE.4,5
A second family of growth factors, the angiopoietins, is
also known for their regulating capacities regarding angio-
genesis.16 Angiopoietin-1 (Ang-1) and angiopoietin-2
(Ang-2) bind with equal affinity to their receptor TIE-2,
but have different functions. Ang-1 maintains vessel
integrity and plays a role in the later stages of vascular
remodeling.16 Ang-2 is a functional antagonist of Ang-1
and leads to loosening of cell–cell interactions and allows
access to angiogenic inducers likeVEGF.17 Coexpression
of VEGF and Ang-2 induces angiogenesis, but Ang-2
results in vascular regression in the absence of angiogenic
signals.18 Ang-1 and Ang-2 have both been detected in
decidual and placental tissues.11,17
Various decidual cell types are capable of producing
angiogenic factors.We recently showed the production of
PlGF, KDR, Flt-1,Ang-2, and TIE-2 by endothelial cells
and extravillous trophoblasts.Decidual stromal cells, glan-
dular epithelium, and perivascular smooth muscle cells
were found to produce all studied angiogenic factors.11
Uterine natural killer cells are also abundantly present in
first-trimester decidua and are known to produce PlGF,
VEGF,Ang-1, and Ang-2.19
The possible correlation of PE and FGR with
impaired vascular development has been studied in pla-
cental tissues mainly after the onset of disease.9,20,21
However, whether decidual vascularization is also related
to the pathogenesis of both diseases is not known.
Information regarding the expression of angiogenic fac-
tors in first-trimester tissues would be helpful in under-
standing PE and FGR.The present study focused on the
role of first-trimester angiogenic growth factors in the
pathogenesis of PE and/or FGR. The expressions of
VEGF-A, PlGF, Flt-1, KDR, Ang-1, Ang-2, and TIE-2
were determined in first-trimester decidua obtained dur-
ing routine chorion villous sampling (CVS). The
included patients were followed throughout their preg-
nancy to be able to relate the angiogenic factor expres-
sion to the pregnancy outcome, that is, uncomplicated,
PE, or FGR.
MATERIALS AND METHODS
Study Group and Tissue Collection
Decidual samples were obtained from viable first-trimester
pregnancies during routine CVS. Chorion villous sam-
pling was performed vaginally between 10 and 12 weeks
of gestation. Main indications were maternal age and
serum screening related risk for aneuploidy. Gestational
age was calculated according to the last menstrual period
and confirmed by ultrasound (crown rump length). After
CVS, surplus decidual tissue was microscopically separated
from the chorion villi and immediately stored at −20°C
until RNA isolation.One sample per person was collected
with an average size of 5 mg to 15 mg.
Follow-up of the pregnancies was available through
a postpartum questionnaire. Patients experiencing FGR
(n = 10) and PE/HELLP (n = 9) were selected.
Preeclampsia was defined as diastolic blood pressure (BP)
of minimal 90 mm Hg, or a raise of 15 mm Hg compared
with first-trimester BP, combined with proteinuria of at
least 300 mg/day. For FGR, criteria according to
Kloosterman22 were used. Birth weight was corrected for
gestational age and FGR was defined as a corrected birth
weight below the 5th percentile. All cases were matched
to controls based on gestational age, maternal age, and
parity at time of CVS (N = 19). Patients with concurrent
morbidity (eg, diabetes) or medication were excluded.
Fetal karyotyping showed no chromosomal abnormali-
ties. Weight and the number of smokers were compara-
ble between cases and controls. Patients were informed
that surplus material was used for research, according to
the “Guideline for Good Use” by the Federation of
Medical Scientific Associations and informed consent
was provided by all study subjects. Patient characteristics
are described in Table 1.
RNA Isolation and cDNA Synthesis
Tissue samples were incubated in 1.5 mL RNA Later Ice
(Ambion,Austin,Texas) for 48 hours at −20°c.After cen-
trifugation, the tissue samples were lysed in lysis buffer
(RLT buffer [Qiagen] and β-mercapto-ethanol) using
plastic mortars and RNA isolation was performed using
RNAeasy columns (Qiagen Benelux BV, Venlo, the
Netherlands) following recommended protocol. mRNA
was dissolved in RNAse-free water.mRNA quantity and
quality was determined by measuring its absorbance in a
spectrophotometer (NanoDrop ND-1000, NanoDrop
 at University of Groningen on January 22, 2009 http://rsx.sagepub.comDownloaded from 
722 Reproductive Sciences Vol. 15, No. 7, September 2008 Plaisier et al
Technologies, Wilmington, Delaware) and reverse tran-
scription was performed with 1 µg total RNA, random
primers, and a cDNA synthesis kit (Ready-to-go You-
Prime first strand beads, Amersham Biosciences,
Buckinghamshire, United Kingdom). The 32 µL of
cDNA obtained was diluted 1:3.
Real-Time Reverse Transcriptase
Polymerase Chain Reaction
mRNA expression was quantified according to theTaqman
real-time polymerase chain reaction (PCR) method using
validated primer and probe (FAM/TAMRA double-
labeled) sets forVEGF-A, Flt-1, KDR, PlGF,Ang-1,Ang-2,
andTIE-2. Glycerlylaldehyde-3-phosphate dehydrogenase
(GAPDH, primers/VIC-labeled probe) was used as an
endogenous reference gene (all purchased from Applied
Biosystems, Foster City, California). β-Actin, β2-
microglobulin, and cyclophilin were also used as refer-
ence genes and showed similar results (data not shown).
RT-PCR for target gene/GAPDH pairs was per-
formed in 12.5-µL reactions, containing 2.5 µL cDNA
solution, using Mastermix (RT-QP2X-03, Eurogentec,
Maastricht, the Netherlands), DNAse-free water, and the
primer/probe sets described above. Reactions were per-
formed in duplicate and mRNA levels were expressed in
cycle threshold (Ct).To correct for the RNA input, the
difference in Ct values of target and reference genes (dCt =
Ct(target gene) − Ct(GAPDH)) was calculated.The dif-
ference between cases and controls (ddCt) was calculated
as ddCt = dCt(case) − dCt(control) and the fold induc-
tion was calculated as 2−ddCt. In addition, Ct values were
quantified into nanograms per microliter (ng/µL) using a
standard curve of total RNA. Cases and controls were
compared by the ratio ng/µL(case)/ng/µL(control).
Water and negative-RT samples, obtained by the omis-
sion of the reverse transcriptase enzyme in the cDNA
reaction, were used as negative controls.
Statistics
The mRNA expression levels were compared between
cases and matched controls. A general linear model for
repeated measurements, analysis of variance, was per-
formed to analyze the paired data between matched cases
and controls (SPSS 11.5). P values <.05 were considered
significant.
RESULTS
The expression of the angiopoietins and their receptor
TIE-2 and ofVEGF, PlGF and their receptors KDR and
Flt-1 were evaluated.The mRNA levels in all cases were
calculated and expressed as ddCt, ng/µL and as fold
induction compared with the control group (Tables 2
and 3). All factors were present at mRNA level in
decidua of cases as well as controls.
Control Group
The control patients were matched to the cases; 10 con-
trols to FGR patients and 9 controls to PE patients. First,
mRNA expression was analyzed in all the control
patients. In these controls, PlGF showed the most abun-
dant expression with a mean of 4.6 ± 1.8 ng/µL. KDR,
Flt-1, and Ang-2 showed a moderate expression with
means of 0.4 ± 0.1, 0.5 ± 0.1, and 0.8 ± 0.3 ng/µL,
respectively.VEGF-A,Ang-1, andTIE-2 were only dimly
Table 1. Characteristics of the FGR and PE Study Groups and Matched Control Groupsa
FGR (n = 10) Control (n = 10) PE/HELLP (n = 9) Control (n = 9)
At CVS
Age (years) 39.5 ± 2.1 39.6 ± 2.1 39.2 ± 1.9 39.2 ± 1.9
GA (days) 75.6 ± 3.2 76.5 ± 2.5 78.6 ± 3.9 77.3 ± 4.4
Parity 1.5 ± 1.4 1.1 ± 0.6 0.7 ± 0.9 0.7 ± 0.9
At delivery
GA (days) 278 ± 11 282 ± 12 261 ± 22 271 ± 10
Birth weight (g) 2477 ± 286b 3648 ± 475 2648 ± 798 3420 ± 382
Abbreviations: FGR, fetal growth restriction; PE, preeclampsia; HELLP, hemolysis, elevated liver enzymes, low platelets; CVS, chorion villous sam-
pling; GA, gestational age.
aData are presented as mean ± standard deviation (mean ± SD).
bP < .05 versus control group.
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expressed with means of 0.04 ± 0.001, 0.01 ± 0.00, and
0.15 ± 0.06 ng/µL, respectively (data not shown).
Fetal Growth Restriction Group
The FGR group showed no significant differential
expression compared with the control group. Strikingly,
the expression of VEGF-A (83-fold), PlGF (31-fold),
KDR (32-fold), Ang-1 (84-fold), Ang-2 (11-fold), and
TIE-2 (34-fold) appeared unregulated in cases compared
with controls. However, significance was not reached due
to the large interindividual variation. Flt-1 showed com-
parable expression levels in cases and controls. The same
pattern was found with regard to calculated ng/µL
(Tables 2 and 3).
Preeclampsia Group
The PE group showed no significant differential expres-
sion compared with the control group. PlGF (51-fold),
Ang-1 (68-fold), and TIE-2 (110-fold) appeared unregu-
lated in cases compared with controls. However, these
differences were not significant due to the large interindi-
vidual variation. VEGF-A, KDR, Flt-1, and Ang-2 showed
comparable expression levels in cases and controls. With
regard to calculated ng/µL, the same pattern was found
(Tables 2 and 3).
DISCUSSION
The results showed that first-trimester decidual tissues
obtained from CVS expressed all examined angiogenic
factors. mRNA levels of VEGF-A, PlGF, KDR, Ang-1,
Ang-2, and TIE-2 appeared unregulated in FGR cases
compared with matched controls. In addition, PlGF,
Ang-1, and TIE-2 mRNA appeared unregulated in PE
cases compared with matched controls. However, the
large interindividual variation disallowed an unequiv-
ocal conclusion. The differential expression of angio-
genic factors appeared more prominent in FGR than
in PE.
The origin of both PE and FGR probably starts in
the first-trimester, before the onset of overt disease dur-
ing the last trimester. Our first-trimester decidual samples
provide a unique opportunity to obtain information
regarding the onset of PE and FGR. The fact that the
decidual samples were obtained together with villous tis-
sue offers valid information on the original localization
in utero, namely underneath the implantation site.
Shortcomings are also present. No histological investiga-
tion could be performed on the number of trophoblasts
and other cell types because of the small amounts of
material in each sample. Also, the study groups are small
because of the rarity of the samples. This results in rather
high standard deviations, which makes interpretation of the
data difficult. However, the 10-fold to 100-fold induction
Table 2.  First-Trimester Decidual mRNA Expression of Angiogenic Factors (in Cycle Threshold, Ct)a,b
mRNA Content (dCt)c Fold Inductiond
Angiogenic Factor FGR (n = 10) PE (n = 9) FGR (n = 10) PE (n = 9)
VEGF-A −1.5 ± 1.2 −0.5 ± 0.8 83 ± 70 3 ± 1
PlGF 0.5 ± 1.6 −2.0 ± 1.4 31 ± 21 51 ± 34
KDR −0.5 ± 1.8 −1.8 ± 1.1 32 ± 25 17 ± 9
Flt-1 0.4 ± 0.6 −1.1 ± 0.7 2 ± 0.9 8 ± 6 
Ang-1 −1.5 ± 1.9 −1.7 ± 1.6 84 ± 50 68 ± 40 
Ang-2 −0.4 ± 1.3 0.1 ± 1.3 11 ± 5 6 ± 5
TIE-2 −1.2 ± 1.5 −3.1 ± 1.3 34 ± 25 110 ± 83
Abbreviations: FGR, fetal growth restriction; PE, preeclampsia.
aFirst-trimester decidual mRNA expression was determined by reverse transcriptase polymerase chain reaction and compared between pregnan-
cies resulting in FGR or PE and their matched controls. The “repeated measures analysis of variance” was performed to analyze the data.
bData are expressed as mean ± standard error of the mean (mean ± SEM).
cmRNA content was expressed in cycle threshold (Ct). Mean Ct per gene: GAPDH, 25; VEGF-A, 26.0; PlGF, 29.2; KDR, 28.5; Flt-1, 28.4;
Ang-1, 33; Ang-2, 27.4; and TIE-2, 32.1. The Ct values were corrected for the mRNA input by calculating the difference in Ct of target and
reference genes: dCt = Ct(target gene) − Ct(GAPDH).
dThe difference between cases and controls (ddCt) was calculated as ddCt= dCt(case) − dCt(control). Fold induction in cases compared with
controls was calculated as 2−ddCt.
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of genes in these small groups promises significant differ-
ences when groups could be expanded.
Current knowledge regarding PE suggests that
defective vascular remodeling of maternal spiral arteries
leads to impaired invasion of trophoblasts, placental insuf-
ficiency, and ischemia.4The affected placenta releases sol-
uble anti-angiogenic factors, like soluble Flt-1 (sFlt-1)
and endoglin (sEng).5,23,24 These factors alter the angio-
genic balance, mainly by neutralizing VEGF and PlGF.
Furthermore, these factors are able to induce systemic
endothelial dysfunction and finally induce clinical PE.5,25-
27 The serum and placental levels of these factors have
been studied extensively in term pregnancies, without
reaching complete consensus with regard to VEGF.
Several reports have described increased, comparable, and
even decreased VEGF levels in placenta of term PE preg-
nancies.9,12,28,29 PlGF was decreased in serum of PE in the
third trimester.20,30 Term placental tissue showed reduced
Ang-2 mRNA and equal Ang-1 mRNA in PE.31 No
reports on these angiogenic factors are available regarding
first-trimester tissues.
In the present study, mRNA levels of PlGF, Ang-1,
and TIE-2 appeared upregulated in future PE patients
compared with controls. VEGF-A, KDR, Flt-1, and Ang-
2 showed comparable expression levels. No previous
reports were found to reference these data in first-
trimester tissues. Only first-trimester serum data are avail-
able, showing reduced PlGF and increased VEGF and
sflt-1 in first-trimester serum of PE patients.32,33
The studied Flt-1 represents both the soluble and
membrane bound Flt-1 and unfortunately no differenti-
ation can be made between both types. The comparable
overall Flt-1 expression in PE cases probably corresponds
to the described decline of membrane bound Flt-1 and
the known increase of soluble Flt-1.34
Fetal growth restriction has been proposed to be
induced by relatively high oxygen levels, which cause a
disturbed expression of angiogenic factors and altered
angiogenesis in placental villi.35-37 These relative hyper-
oxic conditions may cause the decreased VEGF and
increased PlGF expression in FGR placentas because
these factors are inversely regulated by oxygen.38,39 An
ovine model for FGR demonstrated increased Ang-1,
Ang-2, and TIE-2 levels in early gestation before FGR
was clinically detected. Later in gestation, decreased TIE2
expression was associated with FGR.40 Whether decidual
angiogenesis is also affected by the altered oxygen levels
in FGR is still not demonstrated but plausible.
The present study showed that the mRNA levels of
angiogenic factors in first-trimester decidua were altered
in the FGR group compared to the control group,
although differences were not significant. The expression
of VEGF-A, PlGF, KDR, Ang-1, Ang-2, and TIE-2
appeared upregulated in FGR cases and Flt-1 showed
comparable expression levels in cases and controls.
The relative hyperoxia in FGR and the oxygen effect
on angiogenic factors are mainly described in fetoplacen-
tal tissues and trophoblasts. If the theory is valid for
Table 3.  First-Trimester Decidual mRNA Expression of Angiogenic Factorsa,b
mRNA Content (ng/µL)c Fold inductiond
Angiogenic Factor FGR (n = 10) PE (n = 9) FGR (n = 10) PE (n = 9)
VEGF-A 0.1 ± 0.0 0.1 ± 0.0 53 ± 46 2 ± 1
PlGF 4.1 ± 1.8 8.2 ± 3.1 33 ± 21 35 ± 24
KDR 0.7 ± 0.3 1.7 ± 0.8 26 ± 17 13 ± 8
Flt-1 0.6 ± 0.2 2.0 ± 1.3 2 ± 1 3 ± 2
Ang-1 0.02 ± 0.0 0.4 ± 0.4 59 ± 34 29 ± 21
Ang-2 0.4 ± 0.2 3.6 ± 2.0 8 ± 4 5 ± 3
TIE-2 0.9 ± 0.8 19.6 ± 19.5 37 ± 30 68 ± 47
Abbreviations: FGR, fetal growth restriction; PE, preeclampsia.
aFirst-trimester decidual mRNA expression was determined by reverse transcriptase polymerase chain reaction and compared between pregnan-
cies resulting in FGR or PE and their matched controls. The “repeated measures analysis of variance” was performed to analyze the data.
bData are expressed as mean ± standard error of the mean.
cmRNA content was expressed in cycle threshold (Ct). Mean Ct per gene: GAPDH, 25; VEGF-A, 26.0; PlGF, 29.2; KDR, 28.5; Flt-1, 28.4; Ang-
1, 33; Ang-2, 27.4; and TIE-2, 32.1. Cycle threshold were converted into ng/µL using a standard curve of total RNA. Values were corrected for
mRNA input by calculating the ratio [(ng/µL(target gene))/(ng/µL(GAPDH))] and these values are expressed as “mRNA content” in the table.
dFold induction in cases compared with controls was calculated as the ratio ng/µL(case)/ng/µL(controls).
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first-trimester decidua, one would expect decreased
VEGF and Ang-2 and increased Ang-1 and PlGF mRNA
levels in FGR patients.31,37,39,41 However, mRNA levels of
all 4 genes appeared increased in FGR compared with
matched controls. This might be explained by a different
expression and regulation of angiogenic factors in first-
trimester tissues compared with third-trimester tissues.
For example, VEGF-A and Ang-1 were shown to increase
and Ang-2 was shown to decrease as gestation pro-
gresses.9 In contrast, other studies have demonstrated a
decline in VEGF-A mRNA as gestation progresses.42 In
addition, oxygen influences in decidua may differ from its
influences in villous tissue and/or trophoblasts. No refer-
ences were found regarding oxygen regulation in
decidua. Finally, histological differences or differences in
the number of trophoblasts between the studied speci-
mens cannot be ruled out.
The differential expression of angiogenic factors
appeared more prominent in FGR than in PE and there-
fore a more pronounced disbalance between angiogenic
factors might be involved in the pathogenesis of FGR.
Overall, enhanced angiogenic factors in both patient
groups might represent an (ineffective) vascular rescue
mechanism in response to unidentified situation(s) and/or
event(s). This compensatory mechanism may, in turn, unin-
tentionally induce increased nonbranching angiogenesis,
altered decidual and placental vascular adaptation, and
functional placental insufficiency, all of which may result in
PE and/or FGR during late gestation.
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